features: Molecular Profiling
Trastuzumab deruxtecan and the evolving HER2-low breast cancer landscape
VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts…
177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…
Top 5 in lung from ASCO 2021
Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.
Key updates from EAU 2021
VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!
Top 5 in GI from ASCO 2021
VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
Dostarlimab subject to accelerated FDA approval for the treatment of advanced dMMR endometrial cancer
The Food and Drug Administration (FDA) granted accelerated approval to dostarlimab on April 2021 for patients with recurrent or advanced…